Publication date: Sep 12, 2025
Prior to receiving the updated LP. 8.1-targeting vaccine formula, all enrollees had previously received the KP. 2-adapted COVID-19 vaccine. Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP. 8.1-Adapted COVID-19 Vaccine 2025-2026 Formula. Though it was a drop from the prior week, when the test positivity rate was 11. 6%, it is the highest weekly test positivity since September 2024. | Image Credit: diy13 – stock. adobe. comThe findings support the preclinical data that led to the FDA approval of Pfizer-BioNTechs LP. 8.1-adapted COVID-19 vaccine. Halpern L. FDA Approves Updated COVID-19 Vaccines Targeting LP. 8.1 For Older Adults, Those At Risk. Along with that approval, the FDA approved Novavaxs Nuvaxvoid and Modernas Spikevax and mNEXSPIKE, all COVID-19 vaccines that are adapted to target the LP. 8.1 sublineage of SARS-CoV-2. Halpern L. FDA to Restrict Future COVID-19 Vaccine Recommendations to Older Adults, High-Risk Groups.
| Concepts | Keywords |
|---|---|
| Adobe | Accessed |
| Biontech | Adapted |
| Severe | Adults |
| Vaccinationlp | Biontech |
| Covid | |
| Fda | |
| Https | |
| Lp | |
| Older | |
| Pfizer | |
| Risk | |
| September | |
| Vaccine | |
| Vaccines | |
| Www |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Methylphenidate |
| disease | IDO | country |
| disease | MESH | emergency |
| disease | MESH | death |
| disease | IDO | role |
| disease | IDO | immune response |
| drug | DRUGBANK | Coenzyme M |
| disease | MESH | myocarditis |
| pathway | REACTOME | Release |
| disease | MESH | COVID-19 |
| disease | MESH | allergic reaction |